TIMolol Nasal Spray as a Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia (TIM-HHT)—A Prospective, Randomized, Double-Blind, Controlled, Cross-Over Trial

URN to cite this document:: urn:nbn:de:bvb:355-epub-531947
DOI to cite this document:: 10.5283/epub.53194

Andorfer, Kornelia E. C.

; Zeman, Florian ; Koller, Michael ; Zeller, Judith ; Fischer, René ; Seebauer, Caroline T. ; Vielsmeier, Veronika ; Bohr, Christopher ; Kühnel, Thomas S.

License: Creative Commons Attribution 4.0
PDF - Published Version
(1MB)

Date of publication of this fulltext: 14 Nov 2022 14:57

Alternative links to fulltext:DOI Publisher

Details

Preview

Indexed in

Export bibliographical data

Abstract

To date, there is no approved local therapeutic agent for the treatment of epistaxis due to hereditary hemorrhagic telangiectasia (HHT). Several case reports suggest the topical use of timolol. This monocentric, prospective, randomized, placebo-controlled, double-blinded, cross-over study investigated whether the effectiveness of the standard treatment with a pulsed diode laser can be increased ...